Candesartan cilexetil

Synonym
Product Category
Product Code
CAS Number
MDL Number
Pubchem SID
Reaxys RN
TCV 116,TCY 116
API & Intermediates
KAPI0F01
145040-37-5
MFCD00871371
329749217
7328188
image-155171-Trimethyl(trifluoromethyl)silane_reagent.png
Chemical Name
Molecular Formula
Molecular Weight
Assay
Appearance
Melting Point
Packaging
Storage
Candesartan cilexetil
C33H34N6O6
610.66
≥99%(LC&T)
White to Off-white Solid
168-170°C
50g,100g,500g,1kg and 5kg
-20°C Freezer
Candesartan cilexetil(1-(Cyclohexyloxycarbonyloxy)ethyl 1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate) is a typical active pharamaceutical ingredient (API) for the synthesis of antihypertensive drugs. It is the prodrug form of the potent angiotensin II receptor blockers (ARBs, angiotensin II Receptor antagonist). This prodrug is cleaved by esterases within the intestine to liberate the active molecule.
Synthesis and evaluation of novel pyrazolo[1,5-a]pyrimidine derivatives as nonpeptide angiotensin II receptor antagonists. [1]
Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. [2]
Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension - A population analysis. [3]
Solid-state characterization of candesartan cilexetil (TCV-116): Crystal structure and molecular mobility. [4]
Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans. [5]
Identification, synthesis and structural determination of some impurities of candesartan cilexetil. [6]
A noveland practical synthesis of substituted 2-ethoxy benzimidazole: Candesartan cilexetil. [7]
Development of pulsatile drug delivery for chronotherapeutics of hypertension. [8]
References:
[1] R.Kiyama, et al, Chem. Pharm. Bull.(Tokyo), 1995, 43(6), pp 960-965.
[2] Y.Kohara, et al, J. Med. Chem., 1996, 39(26), pp 5228-5235.
[3] I.Meineke, et al, Eur. J. Clin. Pharmacol., 1997, 53(3-4), pp 221-228.
[4] H.Matsunaga, et al, Chem. Pharm. Bull.(Tokyo), 1999, 47(2), pp 182-186.
[5] G.G.Belz, et al, J. Cardiovasc. Pharmacol., 2002, 39(4), pp 561-568.
[6] J.Havlicek, et al, Collect. Czech. Chem. Commun., 2009, 74(2), pp 347-362.
[7] P.Wang, et al, Tetrahedron, 2010, 66(29), pp 5402-5406.
[8] A.Y.Kanugo, et al, Int. J. Drug Deliv. Sci. Technol, 2017, 7(3), PP 184-189.
Signal Word
Hazard Statements
Precautionary Statements
HS Code
RIDADR
Legal Information
Warning
H361,H400
P280
2933998090
NONH for all modes of transport
Sales restrictions may apply.
1. Product Specification
For further information and support on Ph. Eur. Reference Standard, please go to the website of the issuing pharmacopoeia.
For further information and support on USP Reference Standard, please go to the website of the issuing pharmacopoeia.
2. Safety Data Sheet
SDS issued by EDQM can be found here.
SDS issued by USP can be found here.
Please inquire for pricing and availability of this product by writing email to sales@kumidas.com.